A Phase 2B, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, Multicentre Study to Investigate the Efficacy, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 for the Prevention of Migraine

Trial Profile

A Phase 2B, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, Multicentre Study to Investigate the Efficacy, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 for the Prevention of Migraine

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2016

At a glance

  • Drugs ADX-10059 (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 25 Dec 2009 Planned end date changed from 1 Sep 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.
    • 15 Dec 2009 According to an Addex Pharmaceuticals media release, this trial has been prematurely terminated due to abnormalities in liver functions tests.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top